Jubilant To Reorganize With Generics API Business On The Move
Follows Larger Separation Of Life Sciences Business In February
Jubilant Pharmova – formerly Jubilant Life Sciences – plans to separate and move the active pharmaceutical ingredient business currently in the hands of its generic pharmaceuticals subsidiary, taking eventual control of the business itself.
You may also be interested in...
Indian firm Alembic Pharmaceuticals discussed the challenges ahead for its US generics business while revealing a dramatic uptick in non-US overseas markets during its FY2021 financial earnings call.
Jubilant’s board is considering whether to create separate entities for its Pharmaceuticals and Life Science Ingredients business segments to give each greater focus.
Philip Morris once again pledged to up R&D in Vectura after its £1.1bn takeover offer for the UK-based inhalation specialist became unconditional, following the tobacco giant’s acrimonious face-off with private equity Carlyle earlier this year.